Drugs of the future for diarrhea-predominant irritable bowel syndrome: an overview of current investigational drugs

References

• Corsetti M, Whorwell P. Novel pharmacological therapies for irritable bowel syndrome. Expert review of gastroenterology & hepatology. Exp Rev Gastroenterol Hepatol. 2016;10(7):807–815. doi: 10.1586/17474124.2016.1158099
   PubMed Web of Science ®Google Scholar
• Deiana S, Gabbani T, Bagnoli S, et al. Emerging drug for diarrhea predominant irritable bowel syndrome. Expert Opin Emerg Drugs. 2015;20(2):247–261. doi: 10.1517/14728214.2015.1013935
   PubMed Web of Science ®Google Scholar
• Brenner DM, Sayuk GS. Current US food and drug administration-approved pharmacologic therapies for the treatment of irritable bowel syndrome with diarrhea. Advances in therapy. Adv Ther. 2020;37(1):83–96.
   PubMed Web of Science ®Google Scholar
• Camilleri M. Current and future pharmacological treatments for diarrhea-predominant irritable bowel syndrome. Expert Opin Pharmacother. 2013;14(9):1151–1160. doi: 10.1517/14656566.2013.794223
   PubMed Web of Science ®Google Scholar
• Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol. 2012;10(7):712–721. doi: 10.1016/j.cgh.2012.02.029
   PubMed Web of Science ®Google Scholar
• Oka P, Parr H, Barberio B, et al. Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5(10):908–917. doi: 10.1016/S2468-1253(20)30217-X
   PubMed Web of Science ®Google Scholar
• Chen M, Tang TC, Qin D, et al. Pharmacologic treatments for irritable bowel syndrome: an umbrella systematic review. J Gastrointestin Liver Dis. 2020;29(2):199–209. doi: 10.15403/jgld-817
   PubMed Web of Science ®Google Scholar
• Dean BB, Aguilar D, Barghout V, et al. Impairment in work productivity and health-related quality of life in patients with IBS. Am J Manag Care. 2005;11(1 Suppl):S17–26.
   PubMed Web of Science ®Google Scholar
• Colomier E, Algera J, Melchior C. Pharmacological therapies and their clinical targets in irritable bowel syndrome with diarrhea. Front Pharmacol. 2021;11:629026. doi: 10.3389/fphar.2020.629026
   PubMed Web of Science ®Google Scholar
• Mousavi T, Nikfar S, Abdollahi M. An update on efficacy and safety considerations for the latest drugs used to treat irritable bowel syndrome. Expert Opin Drug Metab Toxicol. 2020;16(7):583–604. doi: 10.1080/17425255.2020.1767067
   PubMed Web of Science ®Google Scholar
• Ford AC, Wright-Hughes A, Alderson SL, et al. Amitriptyline at low-dose and titrated for irritable bowel syndrome as second-line treatment in primary care (ATLANTIS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;402(10414):1773–1785. doi: 10.1016/S0140-6736(23)01523-4
   PubMed Web of Science ®Google Scholar
• Lembo A, Sultan S, Chang L, et al. AGA clinical practice guideline on the pharmacological management of irritable bowel syndrome with diarrhea. Gastroenterology. 2022;163(1):137–151. doi: 10.1053/j.gastro.2022.04.017
   PubMed Web of Science ®Google Scholar
• Cash BD, Pimentel M, Rao SSC, et al. Repeat treatment with rifaximin improves irritable bowel syndrome-related quality of life: a secondary analysis of a randomized, double-blind, placebo-controlled trial. Therap Adv Gastroenterol. 2017;10(9):689–699. doi: 10.1177/1756283X17726087
   PubMed Web of Science ®Google Scholar
• Lacy BE, Chang L, Rao SSC, et al. Rifaximin treatment for individual and multiple symptoms of irritable bowel syndrome with diarrhea: an analysis using new end points. Clin Ther. 2023;45(3):198–209. doi: 10.1016/j.clinthera.2023.01.010
   PubMed Web of Science ®Google Scholar
• Khan Z, Khan SK, Reyaz I, et al. Effectiveness of rifaximin on the outcomes of irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials. Cureus. 2023;15(9):e44807. doi: 10.7759/cureus.44807
   PubMed Web of Science ®Google Scholar
• Lucak S, Chang L, Halpert A, et al. Current and emergent pharmacologic treatments for irritable bowel syndrome with diarrhea: evidence-based treatment in practice. Therap Adv Gastroenterol. 2017;10(2):253–275. doi: 10.1177/1756283X16663396
   PubMed Web of Science ®Google Scholar
• Ford AC, Moayyedi P, Chey WD, et al. ACG task force on management of irritable bowel syndrome. American college of gastroenterology monograph on management of irritable bowel syndrome. Am J Gastroenterol. 2018;113(Suppl 2):1–18. doi: 10.1038/s41395-018-0084-x
   PubMedGoogle Scholar
• Liu R, Staller K. Update on eluxadoline for the treatment of irritable bowel syndrome with diarrhea: patient selection and perspectives. Drug Des Devel Ther. 2020;14:1391–1400. doi: 10.2147/DDDT.S216056
   PubMed Web of Science ®Google Scholar
• Li X, Li B, Zhang J, et al. Efficacy of opioid receptor modulators in patients with irritable bowel syndrome: a systematic review and meta-analysis. Medicine (Baltimore). 2021;100(4):e24361. doi: 10.1097/MD.0000000000024361
   PubMed Web of Science ®Google Scholar
• Fragkos KC. Spotlight on eluxadoline for the treatment of patients with irritable bowel syndrome with diarrhea. Clin Exp Gastroenterol. 2017;10:229–240. doi: 10.2147/CEG.S123621
   PubMed Web of Science ®Google Scholar
• Study to explore the therapeutic effect of Eluxadoline in treating irritable bowel syndrome with diarrhea in children. Allergan: ClinicalTrials.gov; 2017 [cited 2023 Dec 18]. Available from: https://classic.clinicaltrials.gov/ct2/show/results/NCT03339128?view=results
   Google Scholar
• Butt I, Kasmin F. Alosetron. StatPearls. Treasure island (FL) ineligible companies. Disclosure: franklin Kasmin declares no relevant financial relationships with ineligible companies: StatPearls publishing copyright © 2023. StatPearls Publishing LLC; 2023.
   Google Scholar
• Rahimi R, Nikfar S, Abdollahi M. Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: a meta-analysis of eight randomized, placebo-controlled, 12-week trials. Clin Ther. 2008;30(5):884–901. doi: 10.1016/j.clinthera.2008.05.002
   PubMed Web of Science ®Google Scholar
• Olden KW, Chey WD, Shringarpure R, et al. Alosetron versus traditional pharmacotherapy in clinical practice: effects on resource use, health-related quality of life, safety and symptom improvement in women with severe diarrhea-predominant irritable bowel syndrome. Curr Med Res Opin. 2019;35(3):461–472. doi: 10.1080/03007995.2018.1533456
   PubMed Web of Science ®Google Scholar
• Tong K, Nicandro JP, Shringarpure R, et al. A 9-year evaluation of temporal trends in alosetron postmarketing safety under the risk management program. Therap Adv Gastroenterol. 2013;6(5):344–357. doi: 10.1177/1756283X13491798
   PubMed Web of Science ®Google Scholar
• Ida M, Nishida A, Akiho H, et al. Randomized, placebo-controlled, phase IV pilot study of ramosetron to evaluate the co-primary end points in male patients with irritable bowel syndrome with diarrhea. Biopsychosoc Med. 2017;11(1):8. doi: 10.1186/s13030-017-0093-9
   PubMedGoogle Scholar
• Zheng Y, Yu T, Tang Y, et al. Efficacy and safety of 5-hydroxytryptamine 3 receptor antagonists in irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials. PloS One. 2017 Mar 14;12(3):e0172846. doi: 10.1371/journal.pone.0172846
   PubMed Web of Science ®Google Scholar
• Qi Q, Zhang Y, Chen F, et al. Ramosetron for the treatment of irritable bowel syndrome with diarrhea: a systematic review and meta-analysis of randomized controlled trials. BMC Gastroenterol. 2018;18(1):5. doi: 10.1186/s12876-017-0734-2
   PubMedGoogle Scholar
• Black CJ, Burr NE, Camilleri M, et al. Efficacy of pharmacological therapies in patients with IBS with diarrhoea or mixed stool pattern: systematic review and network meta-analysis. Gut. 2020 Jan;69(1):74–82.
   PubMed Web of Science ®Google Scholar
• Garsed K, Chernova J, Hastings M, et al. A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea. Gut. 2014;63(10):1617–1625. doi: 10.1136/gutjnl-2013-305989
   PubMed Web of Science ®Google Scholar
• Plasse TF, Barton G, Davidson E, et al. Bimodal release ondansetron improves stool consistency and symptomatology in diarrhea-predominant irritable bowel syndrome: a randomized, double-blind, trial. Am J Gastroenterol. 2020;115(9):1466–1473. doi: 10.14309/ajg.0000000000000727
   PubMed Web of Science ®Google Scholar
• Gunn D, Topan R, Barnard L, et al. Randomised, placebo-controlled trial and meta-analysis show benefit of ondansetron for irritable bowel syndrome with diarrhoea: the TRITON trial. Aliment Pharmacol Ther. 2023;57(11):1258–1271. doi: 10.1111/apt.17426
   PubMed Web of Science ®Google Scholar
• Gunn D, Fried R, Lalani R, et al. Treatment of irritable bowel syndrome with diarrhoea using titrated ondansetron (TRITON): study protocol for a randomised controlled trial. Trials. 2019;20(1):517. doi: 10.1186/s13063-019-3562-6
   PubMedGoogle Scholar
• Goodoory VC, Tuteja AK, Black CJ, et al. Systematic Review and Meta-analysis: Efficacy of Mesalamine in Irritable Bowel Syndrome. Clin Gastroenterol Hepatol: the official clini prac jou of the Ameri Gastro Asso. 2023;22(2): 243–51.
   PubMedGoogle Scholar
• Camilleri M, Vijayvargiya P. The role of bile acids in chronic diarrhea. Am J Gastroenterol. 2020;115(10):1596–1603. doi: 10.14309/ajg.0000000000000696
   PubMed Web of Science ®Google Scholar
• Camilleri M, Acosta A, Busciglio I, et al. Effect of colesevelam on faecal bile acids and bowel functions in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2015;41(5):438–448. doi: 10.1111/apt.13065
   PubMed Web of Science ®Google Scholar
• Vijayvargiya P, Camilleri M, Carlson P, et al. Effects of colesevelam on bowel symptoms, biomarkers, and colonic mucosal gene expression in patients with bile acid diarrhea in a randomized trial. Clin Gastroenterol Hepatol. 2020;18(13):2962–70.e6.
   PubMed Web of Science ®Google Scholar
• Szymaszkiewicz A, Malkiewicz A, Storr M, et al. The place of tachykinin NK2 receptor antagonists in the treatment diarrhea-predominant irritable bowel syndrome. J Physiol Pharmacol. 2019;70(1). doi: 10.26402/jpp.2019.1.01
   PubMed Web of Science ®Google Scholar
• Tack J, Schumacher K, Tonini G, et al. The neurokinin-2 receptor antagonist ibodutant improves overall symptoms, abdominal pain and stool pattern in female patients in a phase II study of diarrhoea-predominant IBS. Gut. 2017;66(8):1403–1413. doi: 10.1136/gutjnl-2015-310683
   PubMed Web of Science ®Google Scholar
• Coughlan S, Das A, O’Herlihy E, et al. The gut virome in irritable bowel syndrome differs from that of controls. Gut Microbes. 2021;13(1):1–15. doi: 10.1080/19490976.2021.1887719
   PubMed Web of Science ®Google Scholar
• A trial for new treatment of adult participants with irritable bowel syndrome. 4D pharma plc: ClinicalTrials.Gov. 2020 [cited 2023 Dec 18]. Available from: https://classic.clinicaltrials.gov/ct2/show/NCT03721107?cond=A+Trial+for+New+Treatment+of+Adult+Participants+With+Irritable+Bowel+Syndrome.&draw=2&rank=1
   Google Scholar
• Study to evaluate the efficacy, safety, and tolerability of BOS-589 in the treatment of patients with diarrhea-predominant irritable bowel syndrome (IBS-D). Boston P: ClinicalTrials.gov; 2020 [cited 2023 Dec 18]. Available from: https://classic.clinicaltrials.gov/ct2/show/NCT03977155?cond=NCT03977155&draw=1&rank=1
   Google Scholar
• A study to investigate the effect of solabegron (GW427353) on gastrointestinal transit in healthy volunteers. GlaxoSmithKline: ClinicalTrials.gov; 2008 [cited 2023 Dec 18]. Available from: https://clinicaltrials.gov/study/NCT00401479?term=NCT00401479&rank=1
   Google Scholar
• Kelleher DH, Hicks KJ, Cox DS, et al. Randomized, double-blind, placebo (PLA)-controlled, crossover study to evaluate efficacy and safety of the beta 3-adrenergic receptor agonist solabegron (SOL) in patients with irritable bowel syndrome (IBS). Neurogastroenterol Motil. 2008;20:131.
   Google Scholar
• Schemann M, Hafsi N, Michel K, et al. The beta3-adrenoceptor agonist GW427353 (Solabegron) decreases excitability of human enteric neurons via release of somatostatin. Gastroenterology. 2010;138(1):266–274.
   PubMed Web of Science ®Google Scholar
• Lacy BE, King J, Shortino D, et al. Efficacy and safety of vibegron for the treatment of irritable bowel syndrome in women: results of a randomized, double-blind, placebo-controlled phase 2 trial. Neurogastroenterol Motil. 2022;34(12):e14448. doi: 10.1111/nmo.14448
   PubMed Web of Science ®Google Scholar
• Castro J, Garcia-Caraballo S, Maddern J, et al. Olorinab (APD371), a peripherally acting, highly selective, full agonist of the cannabinoid receptor 2, reduces colitis-induced acute and chronic visceral hypersensitivity in rodents. Pain. 2022;163(1):e72–e86. doi: 10.1097/j.pain.0000000000002314
   PubMed Web of Science ®Google Scholar
• Yacyshyn BR, Hanauer S, Klassen P, et al. Safety, pharmacokinetics, and efficacy of Olorinab, a peripherally acting, highly selective, full agonist of the cannabinoid receptor 2, in a phase 2a study of patients with chronic abdominal pain associated with Crohn’s disease. Crohn’s & Colitis. 2021;360(1):otaa089. doi: 10.1093/crocol/otaa089
   Google Scholar
• Effect of Olorinab on gastrointestinal transit in patients with irritable bowel syndrome. Arena P: ClinicalTrials.gov; 2021 [cited 2023 Dec 18]. Available from: https://clinicaltrials.gov/study/NCT04655599?term=NCT04655599&rank=1
   Google Scholar
• Chang L, Cash BD, Lembo A, et al. Efficacy and safety of olorinab, a full agonist of the cannabinoid receptor 2, for the treatment of abdominal pain in patients with irritable bowel syndrome: results from a phase 2b randomized placebo-controlled trial (CAPTIVATE). Neurogastroenterol Motil. 2023;35(5):e14539. doi: 10.1111/nmo.14539
   PubMed Web of Science ®Google Scholar
• Wouters MM, Balemans D, Van Wanrooy S, et al. Histamine receptor H1-mediated sensitization of TRPV1 mediates visceral hypersensitivity and symptoms in patients with irritable bowel syndrome. Gastroenterology. 2016;150(4):875–887.
   PubMed Web of Science ®Google Scholar
• Irritable bowel syndrome (IBS) treatment with H1-receptor antagonists. KU Leuven: ClinicalTrials.gov; 2016 [cited 2023 Dec 18]. Available from: https://clinicaltrials.gov/study/NCT01144832?term=NCT01144832&rank=141
   Google Scholar
• Peripheral Histamine 1 Receptor Blockade in IBS: Multicenter Trial. KU Leuven: ClinicalTrials.gov; 2023 [cited 2023 Dec 18]. Available from: https://clinicaltrials.gov/study/NCT01908465?term=NCT01908465&rank=1
   Google Scholar
• Ebastine Versus Mebeverine in IBS Patients. KU Leuven: ClinicalTrials.gov; 2023 [cited 2023 Dec 18]. Available from: https://clinicaltrials.gov/study/NCT05815602?term=NCT05815602&rank=1
   Google Scholar
• A comparison of the effects of ORP-101 versus placebo in adult patients with irritable bowel syndrome with diarrhea (IBS-D). OrphoMed I Ppd: ClinicalTrials.gov; 2021 [cited 2023 Dec 18]. Available from: https://clinicaltrials.gov/study/NCT04129619?term=NCT04129619&rank=1
   Google Scholar
• Efficacy and safety of rifaximin with NAC in IBS-D. Cedars-Sinai Medical C, Bausch Health Ireland L: ClinicalTrials.gov; 2021 [cited 2023 Dec 18]. Available from: https://clinicaltrials.gov/study/NCT04557215?term=Efficacy%20and%20Safety%20of%20Rifaximin%20With%20NAC%20in%20IBS-D&rank=1
   Google Scholar
• Comparing the efficacy of nitazoxanide versus rifaximin in adult patients with irritable bowel syndrome without constipation. Sadat City U: ClinicalTrials.gov; 2023 [cited 2023 Dec 18]. Available from: https://clinicaltrials.gov/study/NCT05453916?intr=Comparing%20the%20Efficacy%20of%20Nitazoxanide%20Versus%20Rifaximin%20in%20Adult%20Patients%20With%20Irritable%20Bowel%20Syndrome%20Without%20Constipation.%20&rank=1
   Google Scholar
• O’Mara AE, Johnson JW, Linderman JD, et al. Chronic mirabegron treatment increases human brown fat, HDL cholesterol, and insulin sensitivity. J Clin Investig. 2020;130(5):2209–2219. doi: 10.1172/JCI131126
   PubMed Web of Science ®Google Scholar
• Dothel G, Barbaro MR, Raschi E, et al. Advancements in drug development for diarrhea-predominant irritable bowel syndrome. Expert Opin Investig Drugs. 2018;27(3):251–263. doi: 10.1080/13543784.2018.1442434
   PubMed Web of Science ®Google Scholar
• Dellis AE, Mozaffari S, Nikfar S, et al. Is there an appropriate strategy for treating co-morbid irritable bowel syndrome and bladder pain syndrome? Expert Opin Pharmacother. 2019;20(4):411–414. doi: 10.1080/14656566.2018.1559821
   PubMed Web of Science ®Google Scholar